Combination therapy using Pentostam and Praziquantel improves lesion healing and parasite resolution in BALB/c mice co-infected with Leishmania major and Schistosoma mansoni

• Published in: Parasites & vectors Vol. 6; no. 1; p. 244
• Main Authors: Khayeka–Wandabwa, Christopher, Kutima, Helen Lydiah, Nyambati, Venny CS, Ingonga, Johnstone, Oyoo–Okoth, Elijah, Karani, Lucy Wanja, Jumba, Bernard, Githuku, Kiige Samuel, Anjili, Christopher O
• Format: Journal Article
• Language: English
• Published: England Springer-Verlag 22-08-2013; BioMed Central Ltd; BioMed Central
• Subjects: Animals; Anthelmintics - administration & dosage; Antimony Sodium Gluconate - administration & dosage; Antiparasitic agents; Body weight; Cancer; Chemotherapy; Coinfection; disease control; Disease transmission; Dosage and administration; Drug therapy; Drug Therapy, Combination; Epidemiology; hosts; Leishmania major; Leishmania major - drug effects; Leishmaniasis; Leishmaniasis, Cutaneous - complications; Leishmaniasis, Cutaneous - drug therapy; Liver; Liver - parasitology; Medical research; Methods; Mice; Mice, Inbred BALB C; mixed infection; parasite load; Parasites; Parasitic diseases; Phosphates; Physiological aspects; praziquantel; Praziquantel - administration & dosage; Schistosoma mansoni; Schistosoma mansoni - drug effects; Schistosomiasis; Schistosomiasis mansoni - complications; Schistosomiasis mansoni - drug therapy; spleen; Spleen - parasitology; Studies; United Kingdom; Germany; Kenya; ANE, Germany; British Isles
• ISSN: 1756-3305; 1756-3305
• DOI: 10.1186/1756-3305-6-244

BACKGROUND: Most natural host populations are exposed to a diversity of parasite communities and co-infection of hosts by multiple parasites is commonplace across a diverse range of systems. Co-infection with Leishmania major and Schistosoma mansoni may have important consequences for disease development, severity and transmission dynamics. Pentavalent antimonials and Praziquantel (PZQ) have been relied upon as a first line of treatment for Leishmania and Schistosoma infections respectively. However, it is not clear how combined therapy with the standard drugs will affect the host and parasite burden in concomitance. The aim of the current study was to determine the efficacy of combined chemotherapy using Pentostam and PZQ in BALB/c mice co-infected with L. major and S. mansoni. METHODS: The study used BALB/c mice infected with L. major and S. mansoni. A 3 × 4 factorial design with three parasite infection groups (Lm, Sm, Lm + Sm designated as groups infected with L. major, S. mansoni and L. major + S. mansoni, respectively) and four treatment regimens [P, PZQ, P + PZQ and PBS designating Pentostam®(GlaxoSmithKline UK), Praziquantel (Biltricide®, Bayer Ag. Leverkusen, Germany), Pentostam + Praziquantel and Phosphate buffered saline] as factors was applied. In each treatment group, there were 10 mice. Lesion development was monitored for 10 weeks. The parasite load, body weight, weight of the spleen and liver were determined between week 8 and week 10. RESULTS: Chemotherapy using the first line of treatment for L. major and S. mansoni reduced the lesion size and parasite loads but did not affect the growth response, spleen and liver. In the co-infected BALB/c mice, the use of Pentostam or PZQ did not result in any appreciable disease management. However, treatment with P + PZQ resulted in significantly (p < 0.05) larger reduction of lesions, net increase in the body weight, no changes in the spleen and liver weight and reduced Leishman-Donovan Units (LDU) and worm counts than BALB/c mice treated with Pentostam or PZQ alone. CONCLUSIONS: The present study demonstrated that the combined first line of treatment is a more effective strategy in managing co-infection of L. major and S. mansoni in BALB/c mice.